vs
Side-by-side financial comparison of Dominari Holdings Inc. (DOMH) and Karyopharm Therapeutics Inc. (KPTI). Click either name above to swap in a different company.
Karyopharm Therapeutics Inc. is the larger business by last-quarter revenue ($34.1M vs $30.1M, roughly 1.1× Dominari Holdings Inc.). Karyopharm Therapeutics Inc. runs the higher net margin — -299.9% vs -438.1%, a 138.2% gap on every dollar of revenue. On growth, Dominari Holdings Inc. posted the faster year-over-year revenue change (220.4% vs 11.6%). Over the past eight quarters, Dominari Holdings Inc.'s revenue compounded faster (369.1% CAGR vs 1.4%).
DOMH vs KPTI — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $30.1M | $34.1M |
| Net Profit | $-131.8M | $-102.2M |
| Gross Margin | — | — |
| Operating Margin | -8.9% | -52.4% |
| Net Margin | -438.1% | -299.9% |
| Revenue YoY | 220.4% | 11.6% |
| Net Profit YoY | -12426.2% | -232.0% |
| EPS (diluted) | $-6.94 | $-7.02 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $30.1M | $34.1M | ||
| Q3 25 | $50.8M | $44.0M | ||
| Q2 25 | $34.1M | $37.9M | ||
| Q1 25 | $8.1M | $30.0M | ||
| Q4 24 | $9.4M | $30.5M | ||
| Q3 24 | $4.0M | $38.8M | ||
| Q2 24 | $6.2M | $42.8M | ||
| Q1 24 | $1.4M | $33.1M |
| Q4 25 | $-131.8M | $-102.2M | ||
| Q3 25 | $125.2M | $-33.1M | ||
| Q2 25 | $16.6M | $-37.3M | ||
| Q1 25 | $-32.5M | $-23.5M | ||
| Q4 24 | $1.1M | $-30.8M | ||
| Q3 24 | $-4.2M | $-32.1M | ||
| Q2 24 | $-6.1M | $23.8M | ||
| Q1 24 | $-5.4M | $-37.4M |
| Q4 25 | -8.9% | -52.4% | ||
| Q3 25 | -3.1% | -34.6% | ||
| Q2 25 | -57.0% | -64.3% | ||
| Q1 25 | -394.6% | -110.8% | ||
| Q4 24 | 0.4% | -102.4% | ||
| Q3 24 | -79.1% | -67.8% | ||
| Q2 24 | -44.3% | -65.7% | ||
| Q1 24 | -205.2% | -101.9% |
| Q4 25 | -438.1% | -299.9% | ||
| Q3 25 | 246.4% | -75.2% | ||
| Q2 25 | 48.7% | -98.2% | ||
| Q1 25 | -400.5% | -78.2% | ||
| Q4 24 | 11.4% | -100.8% | ||
| Q3 24 | -104.2% | -82.7% | ||
| Q2 24 | -99.1% | 55.6% | ||
| Q1 24 | -398.0% | -112.8% |
| Q4 25 | $-6.94 | $-7.02 | ||
| Q3 25 | $7.27 | $-3.82 | ||
| Q2 25 | $1.12 | $-4.32 | ||
| Q1 25 | $-3.02 | $-2.77 | ||
| Q4 24 | $0.21 | $-2.33 | ||
| Q3 24 | $-0.67 | $-3.85 | ||
| Q2 24 | $-1.01 | $-2.97 | ||
| Q1 24 | $-0.91 | $-4.85 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $80.5M | $60.5M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $69.4M | $-292.9M |
| Total Assets | $112.9M | $108.4M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $80.5M | $60.5M | ||
| Q3 25 | $176.2M | $37.7M | ||
| Q2 25 | $28.2M | $38.7M | ||
| Q1 25 | $18.9M | $38.8M | ||
| Q4 24 | $8.2M | $62.5M | ||
| Q3 24 | $7.2M | $72.8M | ||
| Q2 24 | $12.1M | $84.8M | ||
| Q1 24 | $7.1M | $30.6M |
| Q4 25 | $69.4M | $-292.9M | ||
| Q3 25 | $210.2M | $-269.3M | ||
| Q2 25 | $88.6M | $-238.9M | ||
| Q1 25 | $42.4M | $-205.9M | ||
| Q4 24 | $39.9M | $-186.0M | ||
| Q3 24 | $38.3M | $-159.6M | ||
| Q2 24 | $42.4M | $-132.1M | ||
| Q1 24 | $47.7M | $-169.0M |
| Q4 25 | $112.9M | $108.4M | ||
| Q3 25 | $223.4M | $96.2M | ||
| Q2 25 | $109.3M | $104.9M | ||
| Q1 25 | $52.3M | $127.7M | ||
| Q4 24 | $47.1M | $164.4M | ||
| Q3 24 | $43.4M | $189.5M | ||
| Q2 24 | $49.1M | $214.0M | ||
| Q1 24 | $52.2M | $204.5M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $22.7M | $-11.8M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | 0.0% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $22.7M | $-11.8M | ||
| Q3 25 | $-4.9M | $-5.9M | ||
| Q2 25 | $-353.0K | $-18.7M | ||
| Q1 25 | $1.2M | $-39.0M | ||
| Q4 24 | $-16.7M | $-25.8M | ||
| Q3 24 | $-4.7M | $-19.5M | ||
| Q2 24 | $1.4M | $-38.5M | ||
| Q1 24 | $-8.6M | $-43.7M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $-25.9M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | $-43.9M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | -84.7% | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | -132.6% |
| Q4 25 | — | 0.0% | ||
| Q3 25 | — | 0.0% | ||
| Q2 25 | — | 0.0% | ||
| Q1 25 | — | 0.0% | ||
| Q4 24 | — | 0.2% | ||
| Q3 24 | — | 0.0% | ||
| Q2 24 | — | 0.0% | ||
| Q1 24 | — | 0.6% |
| Q4 25 | — | — | ||
| Q3 25 | -0.04× | — | ||
| Q2 25 | -0.02× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | -15.65× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | -1.62× | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
DOMH
| Chief Operating Decision Maker | $30.1M | 100% |
| Commissions | $458.0K | 2% |
KPTI
| Products | $32.1M | 94% |
| License And Other | $2.0M | 6% |
